Papaverine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)

Targets (2)Biointeractions (2)

Identification

Name

Papaverine

Accession Number

DB01113 (APRD00628, DB07725)

Type

Small Molecule

Groups

Approved

Description

An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels. [PubChem]

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Mesotina

External IDs

Not Available

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Papaverine Codecarboxylate	3RX65N0VN7	56896-69-6	VTJFMXLVZKZSGE-UHFFFAOYSA-N	Details
Papaverine Hydrochloride	23473EC6BQ	61-25-6	UOTMYNBWXDUBNX-UHFFFAOYSA-N	Details
Papaverine sulfate	7A476JZB2T	2053-26-1	KYFCEOITJFJQGT-UHFFFAOYSA-N	Details

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Papaverine Hydrochloride Injection USP	Liquid	65 mg	Intramuscular; Intravenous; Subcutaneous	Sandoz Canada Incorporated	1951-12-31	Not applicable	Canada

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Papaverine Hydrochloride	Injection, solution	30 mg/mL	Intravenous	American Regent	1995-09-01	Not applicable	US
Papaverine Hydrochloride	Injection, solution	30 mg/mL	Intravenous	American Regent	1995-09-01	Not applicable	US

International Brands

Name	Company
Alapav	Not Available
Albatran	Not Available
Artegodan	Not Available
Cardioverina	Not Available
Cerebid	Not Available
Cerespan	Not Available
Delapav	Not Available
Dilaves	Not Available
Dispamil	Not Available
Drapavel	Not Available
Durapav	Not Available
Dynovas	Not Available
Mesotina	Not Available
Myobid	Not Available
Optenyl	Not Available
Pameion	Not Available
Pamelon	Not Available
Panergon	Not Available
Papacon	Not Available
Papalease	Not Available
Papaversan	Not Available
Papital T.R.	Not Available
Paptial T.R.	Not Available
Pavabid	Not Available
Pavacap	Not Available
Pavacen	Not Available
Pavadel	Not Available
Pavagen	Not Available
Pavakey	Not Available
Pavased	Not Available
Pavatest	Not Available
Paverolan	Not Available
Paveron	Not Available
Pavnell	Not Available
Qua Bid	Not Available
Ro-Papav	Not Available
Therapav	Not Available
Vasal	Not Available
Vaso-Pav	Not Available

Brand mixtures

Not Available

Categories

UNII

DAA13NKG2Q

CAS number

58-74-2

Weight

Average: 339.385
Monoisotopic: 339.147058165

Chemical Formula

C₂₀H₂₁NO₄

InChI Key

XQYZDYMELSJDRZ-UHFFFAOYSA-N

InChI

InChI=1S/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3

IUPAC Name

1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinoline

SMILES

COC1=C(OC)C=C(CC2=NC=CC3=CC(OC)=C(OC)C=C23)C=C1

Pharmacology

Indication

For the treatment of impotence and vasospasms.

Structured Indications

Not Available

Pharmacodynamics

Papaverine is a nonxanthine phosphodiesterase inhibitor for the relief of cerebral and peripheral ischemia associated with arterial spasm and myocardial ischemia complicated by arrhythmias. The main actions of Papaverine are exerted on cardiac and smooth muscle. Like qathidine, Papaverine acts directly on the heart muscle to depress conduction and prolong the refractory period. Papaverine relaxes various smooth muscles. This relaxation may be prominent if spasm exists. The muscle cell is not paralyzed by Papaverine and still responds to drugs and other stimuli causing contraction. The antispasmodic effect is a direct one, and unrelated to muscle innervation. Papaverine is practically devoid of effects on the central nervous system. Papaverine relaxes the smooth musculature of the larger blood vessels, especially coronary, systemic peripheral, and pulmonary arteries.

Mechanism of action

Perhaps by its direct vasodilating action on cerebral blood vessels, Papaverine increases cerebral blood flow and decreases cerebral vascular resistance in normal subjects; oxygen consumption is unaltered. These effects may explain the benefit reported from the drug in cerebral vascular encephalopathy.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
cAMP-specific 3',5'-cyclic phosphodiesterase 4B	Protein	yes	inhibitor	Human	Q07343	details
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Protein	unknown	inhibitor	Human	Q9Y233	details

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

~90%

Metabolism

Not Available

Route of elimination

Not Available

Half life

0.5-2 hours

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Acebutolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Acebutolol.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Papaverine is combined with Acetazolamide.	Approved, Vet Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Papaverine.	Approved
Aliskiren	The risk or severity of adverse effects can be increased when Papaverine is combined with Aliskiren.	Approved, Investigational
Amifostine	The risk or severity of adverse effects can be increased when Papaverine is combined with Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Papaverine.	Approved
Amiodarone	The risk or severity of adverse effects can be increased when Papaverine is combined with Amiodarone.	Approved, Investigational
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Papaverine.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Papaverine.	Approved, Illicit
Amphotericin B	The risk or severity of adverse effects can be increased when Papaverine is combined with Amphotericin B.	Approved, Investigational
Amyl Nitrite	The risk or severity of adverse effects can be increased when Papaverine is combined with Amyl Nitrite.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Papaverine is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Papaverine.	Approved
Aripiprazole	Aripiprazole may increase the hypotensive activities of Papaverine.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Arotinolol.	Approved
Arsenic trioxide	The risk or severity of adverse effects can be increased when Papaverine is combined with Arsenic trioxide.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Papaverine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Papaverine is combined with Azilsartan medoxomil.	Approved
Barbexaclone	Barbexaclone may increase the hypotensive activities of Papaverine.	Experimental
Barbital	Barbital may increase the hypotensive activities of Papaverine.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Barnidipine.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Papaverine.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Papaverine.	Approved
Bepridil	The risk or severity of adverse effects can be increased when Papaverine is combined with Bepridil.	Approved, Withdrawn
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Papaverine.	Approved
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Papaverine.	Approved
Bortezomib	The risk or severity of adverse effects can be increased when Papaverine is combined with Bortezomib.	Approved, Investigational
Bretylium	The risk or severity of adverse effects can be increased when Papaverine is combined with Bretylium.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Papaverine.	Approved
Bromocriptine	The risk or severity of adverse effects can be increased when Papaverine is combined with Bromocriptine.	Approved, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Papaverine.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Papaverine is combined with Bupivacaine.	Approved, Investigational
Canagliflozin	The risk or severity of adverse effects can be increased when Papaverine is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Papaverine.	Approved
Captopril	The risk or severity of adverse effects can be increased when Papaverine is combined with Captopril.	Approved
Carbetocin	The risk or severity of adverse effects can be increased when Papaverine is combined with Carbetocin.	Approved
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Papaverine.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Papaverine is combined with Carvedilol.	Approved, Investigational
Chlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.	Approved, Vet Approved
Chlorpromazine	The risk or severity of adverse effects can be increased when Papaverine is combined with Chlorpromazine.	Approved, Vet Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Papaverine.	Approved
Cilazapril	The risk or severity of adverse effects can be increased when Papaverine is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Cilnidipine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.	Approved
Clofarabine	The risk or severity of adverse effects can be increased when Papaverine is combined with Clofarabine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Papaverine is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Papaverine.	Approved
Clozapine	The risk or severity of adverse effects can be increased when Papaverine is combined with Clozapine.	Approved
Conivaptan	The risk or severity of adverse effects can be increased when Papaverine is combined with Conivaptan.	Approved, Investigational
Dapagliflozin	The risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Papaverine is combined with Desflurane.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Papaverine.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Papaverine is combined with Diclofenamide.	Approved
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Papaverine.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Papaverine is combined with Dinutuximab.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Papaverine.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.	Approved
Duloxetine	Papaverine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Efonidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Efonidipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Papaverine.	Approved, Vet Approved
Enalaprilat	The risk or severity of adverse effects can be increased when Papaverine is combined with Enalaprilat.	Approved
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Papaverine.	Approved
Epoprostenol	The risk or severity of adverse effects can be increased when Papaverine is combined with Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Papaverine.	Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Papaverine.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.	Approved
Felodipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.	Approved, Investigational
Fenoldopam	The risk or severity of adverse effects can be increased when Papaverine is combined with Fenoldopam.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Papaverine is combined with Fimasartan.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Papaverine.	Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Papaverine.	Approved, Vet Approved
Guanfacine	The risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.	Approved, Investigational
Halothane	The risk or severity of adverse effects can be increased when Papaverine is combined with Halothane.	Approved, Vet Approved
Hexobarbital	Hexobarbital may increase the hypotensive activities of Papaverine.	Approved
Hydralazine	The risk or severity of adverse effects can be increased when Papaverine is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Papaverine.	Approved, Vet Approved
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Papaverine is combined with Hydroflumethiazide.	Approved
Iloprost	The risk or severity of adverse effects can be increased when Papaverine is combined with Iloprost.	Approved, Investigational
Imidapril	The risk or severity of adverse effects can be increased when Papaverine is combined with Imidapril.	Investigational
Imipramine	The risk or severity of adverse effects can be increased when Papaverine is combined with Imipramine.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Papaverine.	Approved
Indoramin	The risk or severity of adverse effects can be increased when Papaverine is combined with Indoramin.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Irbesartan is combined with Papaverine.	Approved, Investigational
Isocarboxazid	The risk or severity of adverse effects can be increased when Papaverine is combined with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Papaverine is combined with Isoflurane.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Papaverine.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Papaverine.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Papaverine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Papaverine.	Approved
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Papaverine.	Approved
Lacidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Lacidipine.	Approved
Lercanidipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Lercanidipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Papaverine is combined with Levobupivacaine.	Approved
Levodopa	Papaverine may increase the hypotensive activities of Levodopa.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Papaverine is combined with Levosimendan.	Approved, Investigational
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Papaverine.	Approved, Investigational
Lofexidine	The risk or severity of adverse effects can be increased when Papaverine is combined with Lofexidine.	Approved, Investigational
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Papaverine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Papaverine.	Approved, Investigational
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Papaverine.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Papaverine.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Papaverine.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Papaverine.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Methyldopa is combined with Papaverine.	Approved
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Papaverine.	Approved
Metipranolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Papaverine.	Approved
Metoprolol	The risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.	Approved, Investigational
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Papaverine.	Approved
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Papaverine.	Approved
Morphine	The risk or severity of adverse effects can be increased when Papaverine is combined with Morphine.	Approved, Investigational
Moxonidine	The risk or severity of adverse effects can be increased when Papaverine is combined with Moxonidine.	Approved
Nabilone	The risk or severity of adverse effects can be increased when Papaverine is combined with Nabilone.	Approved, Investigational
Nadolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Nadolol.	Approved
Nebivolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Nebivolol.	Approved, Investigational
Nesiritide	The risk or severity of adverse effects can be increased when Papaverine is combined with Nesiritide.	Approved, Investigational
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Papaverine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Papaverine.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Nifedipine.	Approved
Nilvadipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Nilvadipine.	Approved
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Papaverine.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Papaverine.	Approved
Nitrendipine	The risk or severity of adverse effects can be increased when Papaverine is combined with Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Papaverine is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.	Approved, Investigational
Nitroprusside	The risk or severity of adverse effects can be increased when Nitroprusside is combined with Papaverine.	Approved
Obinutuzumab	The risk or severity of adverse effects can be increased when Papaverine is combined with Obinutuzumab.	Approved
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.	Approved, Investigational
Oxprenolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Oxprenolol.	Approved
Paclitaxel	The risk or severity of adverse effects can be increased when Papaverine is combined with Paclitaxel.	Approved, Vet Approved
Penbutolol	The risk or severity of adverse effects can be increased when Papaverine is combined with Penbutolol.	Approved, Investigational
Pentobarbital	Pentobarbital may increase the hypotensive activities of Papaverine.	Approved, Vet Approved
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.	Approved
Phenelzine	The risk or severity of adverse effects can be increased when Papaverine is combined with Phenelzine.	Approved
Phenobarbital	Phenobarbital may increase the hypotensive activities of Papaverine.	Approved
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Papaverine is combined with Phenoxybenzamine.	Approved
Phentolamine	The risk or severity of adverse effects can be increased when Papaverine is combined with Phentolamine.	Approved
Pindolol	The risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.	Approved
Pipamperone	The risk or severity of adverse effects can be increased when Papaverine is combined with Pipamperone.	Approved
Pramipexole	The risk or severity of adverse effects can be increased when Papaverine is combined with Pramipexole.	Approved, Investigational
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Papaverine.	Approved
Primidone	Primidone may increase the hypotensive activities of Papaverine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Papaverine is combined with Propofol.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Papaverine.	Approved, Investigational
Quetiapine	The risk or severity of adverse effects can be increased when Papaverine is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Papaverine.	Approved, Investigational
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Papaverine.	Approved
Rasagiline	The risk or severity of adverse effects can be increased when Papaverine is combined with Rasagiline.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Papaverine is combined with Remifentanil.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Papaverine.	Approved
Riociguat	The risk or severity of adverse effects can be increased when Papaverine is combined with Riociguat.	Approved
Risperidone	Papaverine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ropinirole	The risk or severity of adverse effects can be increased when Papaverine is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Papaverine is combined with Ropivacaine.	Approved
Rotigotine	The risk or severity of adverse effects can be increased when Papaverine is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Papaverine is combined with Sacubitril.	Approved
Secobarbital	Secobarbital may increase the hypotensive activities of Papaverine.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Papaverine is combined with Selegiline.	Approved, Investigational, Vet Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Papaverine is combined with Sevoflurane.	Approved, Vet Approved
Sodium Nitrite	The risk or severity of adverse effects can be increased when Papaverine is combined with Sodium Nitrite.	Approved
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Papaverine.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Papaverine is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Papaverine is combined with Sufentanil.	Approved, Investigational
Tamsulosin	The risk or severity of adverse effects can be increased when Papaverine is combined with Tamsulosin.	Approved, Investigational
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine.	Approved, Investigational
Terazosin	The risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.	Approved
Thalidomide	The risk or severity of adverse effects can be increased when Papaverine is combined with Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	Thiamylal may increase the hypotensive activities of Papaverine.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Papaverine.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Papaverine is combined with Thioridazine.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Papaverine.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Papaverine.	Approved
Tolazoline	The risk or severity of adverse effects can be increased when Papaverine is combined with Tolazoline.	Approved, Vet Approved
Tolcapone	The risk or severity of adverse effects can be increased when Papaverine is combined with Tolcapone.	Approved, Withdrawn
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Papaverine.	Approved
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Papaverine.	Approved
Tranylcypromine	The risk or severity of adverse effects can be increased when Papaverine is combined with Tranylcypromine.	Approved
Tretinoin	The risk or severity of adverse effects can be increased when Papaverine is combined with Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Papaverine.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Papaverine.	Approved, Investigational
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Papaverine.	Approved

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Tang Y, Luan J, Zhang X: Accelerating tissue expansion by application of topical papaverine cream. Plast Reconstr Surg. 2004 Oct;114(5):1166-9. [PubMed:15457029 ]
Liu JK, Couldwell WT: Intra-arterial papaverine infusions for the treatment of cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2005;2(2):124-32. [PubMed:16159054 ]
Takeuchi K, Sakamoto S, Nagayoshi Y, Nishizawa H, Matsubara J: Reactivity of the human internal thoracic artery to vasodilators in coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004 Nov;26(5):956-9. [PubMed:15519189 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15245
KEGG Drug	D07425
KEGG Compound	C06533
PubChem Compound	4680
PubChem Substance	46508003
ChemSpider	4518
BindingDB	14754
ChEBI	28241
ChEMBL	CHEMBL19224
Therapeutic Targets Database	DAP000959
PharmGKB	PA164745550
HET	EV1
Drug Product Database	6941
RxList	http://www.rxlist.com/cgi/generic/papaverine.htm
Drugs.com	http://www.drugs.com/cdi/papaverine.html
Wikipedia	Papaverine

ATC Codes

G04BE02 — Papaverine

G04BE52 — Papaverine, combinations

A03AD01 — Papaverine

AHFS Codes

24:12.92

PDB Entries

Not Available

FDA label

Not Available

MSDS

Download (74.4 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Not Yet Recruiting	Treatment	Prostatic Hyperplasia	1
0	Terminated	Health Services Research	Cognitive Deficits / Schizophrenic Disorders	1
2	Completed	Supportive Care	Malignant Neoplasm of Prostate	1
3	Terminated	Treatment	Gastroenteritis	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Dosage forms

Form	Route	Strength
Injection, solution	Intravenous	30 mg/mL
Liquid	Intramuscular; Intravenous; Subcutaneous	65 mg

Prices

Unit description	Cost	Unit
Papaverine 150 mg capsule sa	1.86USD	capsule
Papaverine 60 mg/2 ml vial	1.68USD	ml
Papaverine hcl powder	0.76USD	g
Para-time 150 mg capsule sa	0.23USD	capsule

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	226 (dec) °C	PhysProp
logP	3	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0129 mg/mL	ALOGPS
logP	4.19	ALOGPS
logP	3.08	ChemAxon
logS	-4.4	ALOGPS
pKa (Strongest Basic)	6.03	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	49.81 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	95.52 m³·mol^-1	ChemAxon
Polarizability	36.57 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9911
Blood Brain Barrier	+	0.9633
Caco-2 permeable	+	0.8866
P-glycoprotein substrate	Non-substrate	0.5389
P-glycoprotein inhibitor I	Non-inhibitor	0.6485
P-glycoprotein inhibitor II	Non-inhibitor	0.8005
Renal organic cation transporter	Non-inhibitor	0.7229
CYP450 2C9 substrate	Non-substrate	0.796
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Substrate	0.6263
CYP450 1A2 substrate	Inhibitor	0.9107
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Inhibitor	0.8448
CYP450 2C19 inhibitor	Inhibitor	0.778
CYP450 3A4 inhibitor	Inhibitor	0.7959
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8558
Ames test	Non AMES toxic	0.689
Carcinogenicity	Non-carcinogens	0.9503
Biodegradation	Not ready biodegradable	0.9262
Rat acute toxicity	2.9877 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9329
hERG inhibition (predictor II)	Non-inhibitor	0.7274

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0006-0009000000-376bdab66f9ada8143f2	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-0f6x-0049000000-fbf8945b1b40a8e629ff	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-QTOF , positive	splash10-00di-0779000000-37837168aff5cb2db6db	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0006-0019000000-175d5d7601656bade9be	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-00dl-0569000000-1f7e7c97dcea64bf274a	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Isoquinolines and derivatives

Sub Class

Benzylisoquinolines

Direct Parent

Benzylisoquinolines

Alternative Parents

Dimethoxybenzenes / Phenoxy compounds / Anisoles / Alkyl aryl ethers / Pyridines and derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives

Substituents

Benzylisoquinoline / O-dimethoxybenzene / Dimethoxybenzene / Phenoxy compound / Anisole / Phenol ether / Methoxybenzene / Alkyl aryl ether / Monocyclic benzene moiety / Pyridine

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

benzylisoquinoline alkaloid, dimethoxybenzene, isoquinolines (CHEBI:28241 ) / Isoquinoline alkaloids (C06533 )

Targets

Details

1. cAMP-specific 3',5'-cyclic phosphodiesterase 4B

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Metal ion binding
Specific Function:: Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging from antidepressants to antiasthmatic and anti-inflammatory agents.
Gene Name:: PDE4B
Uniprot ID:: Q07343
Molecular Weight:: 83342.695 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Xin ZC, Kim EK, Lin CS, Liu WJ, Tian L, Yuan YM, Fu J: Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8. [PubMed:12646997 ]
Zhu S, Gan Z, Li Z, Liu Y, Yang X, Deng P, Xie Y, Yu M, Liao H, Zhao Y, Zhao L, Liao F: The measurement of cyclic nucleotide phosphodiesterase 4 activities via the quantification of inorganic phosphate with malachite green. Anal Chim Acta. 2009 Mar 16;636(1):105-10. doi: 10.1016/j.aca.2009.01.035. Epub 2009 Jan 22. [PubMed:19231363 ]

Details

2. cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Metal ion binding
Specific Function:: Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.
Gene Name:: PDE10A
Uniprot ID:: Q9Y233
Molecular Weight:: 88411.71 Da

References

Weber M, Breier M, Ko D, Thangaraj N, Marzan DE, Swerdlow NR: Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine. Psychopharmacology (Berl). 2009 May;203(4):723-35. doi: 10.1007/s00213-008-1419-x. Epub 2008 Dec 9. [PubMed:19066855 ]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:56

Get DrugBank to go!

Structure for DB01113 (Papaverine)

Targets

References

References